Drugs / Lactobacillus reuteri Prodentis
Lactobacillus reuteri Prodentis
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT07489924 | Jan 2023 → Jul 2025 overdue | periodontitis, type 2 diabetes mellitus | University of Colima | Active not recruiting | No outcome recorded |
| Phase 4 | NCT03047291 | Jan 2014 → Mar 2017 | mucositis, periodontal disorder | Universitat Internacional de Catalunya | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lactobacillus reuteri Prodentis | “the oral probiotic Lactobacillus reuteri Prodentis (PerioBalance®, Sunstar, Switzerland)” NCT03047291 ↗ |
| Known as | BioGaia ProD | “BioGaia® ProD (L. reuteri Prodentis); dosage: 1 buccodispersible tablet per day (2×10⁸), for 30 days.” NCT07489924 ↗ |
| Known as | L. reuteri Prodentis | “BioGaia® ProD (L. reuteri Prodentis); dosage: 1 buccodispersible tablet per day (2×10⁸), for 30 days.” NCT07489924 ↗ |
| Known as | PerioBalance | “the oral probiotic Lactobacillus reuteri Prodentis (PerioBalance®, Sunstar, Switzerland)” NCT03047291 ↗ |
| Modality | Other / unclassified | “as a probiotic agent” PMID 23176716 ↗ Nov 2012 |
| Route | Oral | “oral administration of Lactobacillus reuteri Prodentis improved the short-term clinical outcomes” PMID 23176716 ↗ Nov 2012 |